Abstract
Two-component systems (TCS) involving the His-Asp phosphotransfer are commonly utilized for signal transduction in prokaryotes in which the two essential components are a sensor histidine kinase (HK) receptor and a response regulator (RR). Despite great efforts in structural and functional characterization of signal perception mechanisms, the exact signaling mechanisms remain elusive for many TCSs. Mimicking the natural TCS signaling pathways, chimeric receptor kinases and response regulators have been constructed through the process of swapping modular domains of related TCSs. To design chimeras with new signaling pathways, domains from different proteins that have little relationship at the primary structural level but carrying desirable functional properties can be conjoined to engineer novel TCSs. These chimeras maintain the ability to respond to environmental stimulants by regulating protein phosphorylation to produce downstream output signals. Depending on the nature of external signals, chimeric TCSs can serve as a novel tool not only to examine the natural signaling mechanisms in TCSs, but also for industrial and clinical applications.
Keywords: Chimera, histidine kinase, phosphotransfer, protein engineering, response regulator, signal transduction, two-component system
Protein & Peptide Letters
Title: Protein Engineering of Bacterial Histidine Kinase Receptor Systems
Volume: 17 Issue: 7
Author(s): Wei Xie, Katherine Y. Blain, Mario Meng-Chiang Kuo and Senyon Choe
Affiliation:
Keywords: Chimera, histidine kinase, phosphotransfer, protein engineering, response regulator, signal transduction, two-component system
Abstract: Two-component systems (TCS) involving the His-Asp phosphotransfer are commonly utilized for signal transduction in prokaryotes in which the two essential components are a sensor histidine kinase (HK) receptor and a response regulator (RR). Despite great efforts in structural and functional characterization of signal perception mechanisms, the exact signaling mechanisms remain elusive for many TCSs. Mimicking the natural TCS signaling pathways, chimeric receptor kinases and response regulators have been constructed through the process of swapping modular domains of related TCSs. To design chimeras with new signaling pathways, domains from different proteins that have little relationship at the primary structural level but carrying desirable functional properties can be conjoined to engineer novel TCSs. These chimeras maintain the ability to respond to environmental stimulants by regulating protein phosphorylation to produce downstream output signals. Depending on the nature of external signals, chimeric TCSs can serve as a novel tool not only to examine the natural signaling mechanisms in TCSs, but also for industrial and clinical applications.
Export Options
About this article
Cite this article as:
Xie Wei, Y. Blain Katherine, Meng-Chiang Kuo Mario and Choe Senyon, Protein Engineering of Bacterial Histidine Kinase Receptor Systems, Protein & Peptide Letters 2010; 17 (7) . https://dx.doi.org/10.2174/092986610791306706
DOI https://dx.doi.org/10.2174/092986610791306706 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Regulatory Cascade of Neuronal Loss and Glucose Metabolism
CNS & Neurological Disorders - Drug Targets Translational Methods for Non-Invasive Electrical Stimulation to Facilitate Gait Rehabilitation Following Stroke - The Future Directions
Neuroscience and Biomedical Engineering (Discontinued) Synthesis and Characterization of a Nylon/Titanium as Hybrid Biomaterial
Recent Patents on Corrosion Science Hypoxic Radiosensitizers and Hypoxic Cytotoxins in Radiation Oncology
Current Medicinal Chemistry - Anti-Cancer Agents Discovery and Optimization of Pyrazoline Derivatives As Promising Monoamine Oxidase Inhibitors
Current Topics in Medicinal Chemistry Insulin and the Future Treatment of Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Histone Deacetylase Inhibitors In Inflammatory Disease
Current Topics in Medicinal Chemistry Bipolar Affective Disorder, Epilepsy and Migraine – Does Possible Shared Pathogenesis Explain their Association?
Current Psychopharmacology Medicinal Electrochemistry: Integration of Electrochemistry, Medicinal Chemistry and Computational Chemistry
Current Medicinal Chemistry Protein Engineering: A New Frontier for Biological Therapeutics
Current Drug Metabolism Pyrazoline: A Promising Scaffold for the Inhibition of Monoamine Oxidase
Central Nervous System Agents in Medicinal Chemistry VaD - An Integrated Framework for Cognitive Rehabilitation
CNS & Neurological Disorders - Drug Targets Subject Index To Volume-3
Letters in Organic Chemistry Protein-Labs on Separative Analytical Scale in Medicinal Chemistry: from the Proof of Concept to Applications
Current Organic Chemistry Simultaneous Determination of D-amino Acids in Rat Urine by Highperformance Liquid Chromatography-tandem Mass Spectrometry Method: Application to Investigate the Clinical Value of D-amino Acids in the Early Diagnosis of Alzheimer’s Disease
Current Pharmaceutical Analysis Risk Factors, CD4 Long-Term Evolution and Mortality of HIV-Infected Patients who Persistently Maintain Low CD4 Counts, Despite Virological Response to HAART
Current HIV Research Adherence to Antiretroviral Therapy Among Iranian HIV/AIDS Patients
Current Clinical Pharmacology Patterns of Cognitive Impairment in Neurological Disease
Current Psychiatry Reviews Effects of Tobacco Nicotine-Derived Nitrosamine Ketone (NNK) Exposures on Brain Alcohol Metabolizing Enzyme Activities
Drug Metabolism Letters Editorial [Hot Topic: Ion Channels as Therapeutic Targets for Neuropathic Pain (Executive Editor: Char-Chang Shieh)]
Current Pharmaceutical Design